Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by fredgoodwinsonon Jun 10, 2020 3:48pm
150 Views
Post# 31135243

RE:RE:RE:RE:RE:RE:RE:RE:Not Worried About SP...

RE:RE:RE:RE:RE:RE:RE:RE:Not Worried About SP...

Guess that they are limited as to where they initially trial Rutherrin by a long-term research association with Princess Margaret/UHN and the Ontario grant.

 

If it`s GBM it seems that Lilge Betz Cassidy and Co.have optimised light activation of the compound to their satisfaction in respect of interstitial treatment but there are a lot of variables here including - tantalisingly - the potential use of trans-cranial x-ray as well as multiple adjuvants (cannabinoid, vaccine etc.) so definition of the Clinical Protocol is likely still ongoing.

 

We’ve been told little of progress on the science side since the OSC debacle. Have held other biotechs where hope and share price have been sustained for many years with a lot less ammo than the Management have here.

 

Can only hope that as soon as they are ready they are able to press the button but in the meantime Shareholders deserve more than this.

 

 

Bullboard Posts